Znomics, Inc.

Znomics is a biotechnology company utilizing proprietary zebrafish technologies to uncover new drug targets and pharmaceuticals to treat complex human diseases. The company has developed a novel drug discovery methodology based on high throughput, in vivo drug screening against human disease models in zebrafish. This methodology screens against all potential drug targets in the animal and improves the speed and efficacy of finding lead compounds, as compared with the single target screens traditionally used in the pharmaceutical industry.

Znomics' new drug discovery approach is based on the ZeneMark® Library, the Company's proprietary database of retroviral mutations in the zebrafish. The ZeneMark Library currently contains more than 11,000 strains of fish representing mutations in more than half of the known zebrafish genes. The Company is leveraging this technology for its internal drug discovery efforts, as well as building collaborative alliances with pharmaceutical companies and universities. The Company also provides mutant fish strains to university scientists, for research purposes.